JP2023081969A5 - - Google Patents
Info
- Publication number
- JP2023081969A5 JP2023081969A5 JP2023034511A JP2023034511A JP2023081969A5 JP 2023081969 A5 JP2023081969 A5 JP 2023081969A5 JP 2023034511 A JP2023034511 A JP 2023034511A JP 2023034511 A JP2023034511 A JP 2023034511A JP 2023081969 A5 JP2023081969 A5 JP 2023081969A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- tlr2 agonist
- agonist
- compound
- lipid moiety
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2017901180A AU2017901180A0 (en) | 2017-03-31 | Treatment of respiratory infection | |
| AU2017901180 | 2017-03-31 | ||
| AU2017905124A AU2017905124A0 (en) | 2017-12-21 | Treatment of respiratory infection (2) | |
| AU2017905128 | 2017-12-21 | ||
| AU2017905128A AU2017905128A0 (en) | 2017-12-21 | Optimised compounds | |
| AU2017905124 | 2017-12-21 | ||
| AU2018900409A AU2018900409A0 (en) | 2018-02-09 | Treatment of respiratory infection (3) | |
| AU2018900409 | 2018-02-09 | ||
| JP2019552871A JP7719590B2 (ja) | 2017-03-31 | 2018-03-29 | Ｔｌｒアゴニストによる呼吸器感染症の治療 |
| PCT/AU2018/050295 WO2018176099A1 (en) | 2017-03-31 | 2018-03-29 | Treatment of respiratory infection with a tlr2 agonist |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019552871A Division JP7719590B2 (ja) | 2017-03-31 | 2018-03-29 | Ｔｌｒアゴニストによる呼吸器感染症の治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023081969A JP2023081969A (ja) | 2023-06-13 |
| JP2023081969A5 true JP2023081969A5 (enExample) | 2025-11-06 |
| JP7795489B2 JP7795489B2 (ja) | 2026-01-07 |
Family
ID=63673872
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019552871A Active JP7719590B2 (ja) | 2017-03-31 | 2018-03-29 | Ｔｌｒアゴニストによる呼吸器感染症の治療 |
| JP2023034511A Active JP7795489B2 (ja) | 2017-03-31 | 2023-03-07 | Ｔｌｒアゴニストによる呼吸器感染症の治療 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019552871A Active JP7719590B2 (ja) | 2017-03-31 | 2018-03-29 | Ｔｌｒアゴニストによる呼吸器感染症の治療 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20200147028A1 (enExample) |
| EP (1) | EP3600374B1 (enExample) |
| JP (2) | JP7719590B2 (enExample) |
| CN (2) | CN110461351B (enExample) |
| AU (1) | AU2018241248B2 (enExample) |
| ES (1) | ES2979287T3 (enExample) |
| PL (1) | PL3600374T3 (enExample) |
| WO (1) | WO2018176099A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2811957C (en) | 2010-09-22 | 2019-04-16 | The University Of Melbourne | Soluble tlr2 moiety for use in the treatment or prevention of respiratory conditions associated with infectious agents |
| IL275360B2 (en) * | 2017-12-21 | 2023-10-01 | Axelia Oncology Pty Ltd | Optimal compounds |
| WO2019119069A1 (en) * | 2017-12-21 | 2019-06-27 | Ena Therapeutics Pty Ltd | Administration of a tlr2 agonist for the treatment or prevention of a respiratory condition associated with an infectious agent |
| NZ783377A (en) * | 2019-06-26 | 2026-03-27 | Ena Respiratory Pty Ltd | Pegylated novel molecules for agonising tlr2 |
| WO2021042174A1 (en) * | 2019-09-04 | 2021-03-11 | Ena Therapeutics Pty Ltd | Cancer treatment |
| JP2022546806A (ja) * | 2019-09-04 | 2022-11-09 | アクセリア オンコロジー ピーティーワイ リミテッド | 癌免疫療法 |
| US20230346829A1 (en) * | 2020-05-11 | 2023-11-02 | Revir, Inc. | Compositions and methods for treating viral infections |
| AU2021278377A1 (en) * | 2020-05-26 | 2022-12-15 | Ena Respiratory Pty Ltd | Treatment of coronavirus |
| AU2021294603A1 (en) * | 2020-06-26 | 2022-12-15 | Ena Respiratory Pty Ltd | Branched lipid compounds |
| EP4395761A4 (en) * | 2021-08-31 | 2025-10-01 | Ena Respiratory Pty Ltd | ALLERGY TREATMENT |
| AU2022338350A1 (en) * | 2021-09-02 | 2024-02-29 | Ena Respiratory Pty Ltd | Formulation |
| CN114539356B (zh) * | 2022-02-21 | 2023-06-09 | 中国人民解放军陆军军医大学 | 一种脂肽及其制备方法和应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4119856A1 (de) | 1991-06-17 | 1992-12-24 | Hoechst Ag | N-acyl-s-(2-hydroxyalkyl)-cysteine, deren herstellung sowie deren verwendung als zwischenprodukte zur herstellung von synthetischen immunadjuvantien und synthetischen impfstoffen |
| US7723303B2 (en) * | 2000-08-24 | 2010-05-25 | The Regents Of The University Of California | Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response |
| NZ536796A (en) * | 2002-04-25 | 2007-03-30 | Scripps Research Inst | Treatment and prevention of pulmonary conditions comprising at least one lung surfactant polypeptide and at least one protease inhibitor, lipase inhibitor or an anti-oxidant |
| WO2005079419A2 (en) * | 2004-02-17 | 2005-09-01 | The Regents Of The University Of California | Methods of treating immunopathological disorders |
| JP2008500289A (ja) * | 2004-05-27 | 2008-01-10 | ノヴォザイムズ グロペップ リミテッド | 炎症性気道疾患の治療 |
| WO2009137103A2 (en) * | 2008-05-09 | 2009-11-12 | Ourth Donald D | Anti-cancer/anti-viral compounds and methods of use |
| WO2010115229A1 (en) | 2009-04-09 | 2010-10-14 | The University Of Melbourne | Immunogenic composition and uses thereof |
| EA031379B1 (ru) * | 2010-03-23 | 2018-12-28 | Новартис Аг | Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний |
| CA2811957C (en) * | 2010-09-22 | 2019-04-16 | The University Of Melbourne | Soluble tlr2 moiety for use in the treatment or prevention of respiratory conditions associated with infectious agents |
| IN2014CN02581A (enExample) * | 2011-10-06 | 2015-08-07 | Immunovaccine Technologies Inc | |
| US20170274068A1 (en) * | 2014-09-12 | 2017-09-28 | The University Of Melbourne | Immunological reagent |
-
2018
- 2018-03-29 AU AU2018241248A patent/AU2018241248B2/en active Active
- 2018-03-29 US US16/495,829 patent/US20200147028A1/en active Pending
- 2018-03-29 ES ES18774987T patent/ES2979287T3/es active Active
- 2018-03-29 CN CN201880020768.1A patent/CN110461351B/zh active Active
- 2018-03-29 EP EP18774987.4A patent/EP3600374B1/en active Active
- 2018-03-29 PL PL18774987.4T patent/PL3600374T3/pl unknown
- 2018-03-29 JP JP2019552871A patent/JP7719590B2/ja active Active
- 2018-03-29 CN CN202410307367.1A patent/CN118161614A/zh active Pending
- 2018-03-29 WO PCT/AU2018/050295 patent/WO2018176099A1/en not_active Ceased
-
2023
- 2023-03-07 JP JP2023034511A patent/JP7795489B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7744166B2 (ja) | ステロイドの抗痙攣活性 | |
| JP2020512336A5 (enExample) | ||
| JP7795489B2 (ja) | Ｔｌｒアゴニストによる呼吸器感染症の治療 | |
| CN110603037A (zh) | 普那布林的组合物及其用途 | |
| JP2006502969A (ja) | 内因性性腺刺激ホルモン産生の増強 | |
| RU2018115685A (ru) | Фармацевтическая композиция | |
| AU2004241746A1 (en) | Salmeterol and ciclesonide combination | |
| JP2008110991A (ja) | 処置方法 | |
| JP2004500430A (ja) | ホルモテロール及びブデソニドを含有する医薬用の組み合わせ | |
| JP2016510012A5 (enExample) | ||
| KR20200101428A (ko) | 최적화된 화합물 | |
| AU2015261103A1 (en) | Combinations of tiotropium bromide, formoterol and budesonide for the treatment of COPD | |
| JP2012505236A (ja) | コルチコステロイド組成物およびそれの治療方法 | |
| CA2538419A1 (en) | Use of ciclesonide for the treatment of respiratory diseases | |
| EP2934479A1 (en) | Ciclesonide for the treatment of airway disease in horses | |
| CN111971027A (zh) | 副甲状腺素类似物的口服制剂及治疗 | |
| EP4333809A1 (en) | Liposome-encapsulated corticosteriods inhibit sars-cov-2 replication and reduces lung inflammation | |
| Sato et al. | Efficacy of mepolizumab extended interval dosing for 2 asthmatic patients with chronic eosinophilic pneumonia | |
| JP2023539344A5 (enExample) | ||
| JP4755495B2 (ja) | 組合せ医薬品 | |
| JP2004500431A (ja) | （ｒ，ｒ）−ホルモテロール及びロフレポニドを含む医薬組成物 | |
| JP2007533706A5 (enExample) | ||
| CN115397433A (zh) | 含有海藻糖或海藻糖衍生物的药物和鼻喷雾剂 | |
| JP2007515401A5 (enExample) | ||
| EP4319790A1 (en) | Methods of treatment of pediatric puberty using oral formulations of leuprolide |